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Background: Sortase A (SrtA) is a transpeptidase 
capable of catalyzing the formation of amide 
bonds. 
Results: SrtA was used to backbone cyclize 
disulfide-rich peptides, including kalata B1, α-
conotoxin Vc1.1 and SFTI-1. 
Conclusion: SrtA-mediated cyclization is 
applicable to small disulfide-rich peptides. 
Significance: SrtA-mediated cyclization is an 
alternative to native chemical ligation for the 
cyclization of small peptides of therapeutic interest. 
 
ABSTRACT 
    Disulfide-rich cyclic peptides have generated 
great interest in the development of peptide-
based therapeutics due to their exceptional 
stability towards chemical, enzymatic or 
thermal attack. In particular, they have been 
used as scaffolds onto which bioactive epitopes 
can be grafted to take advantage of the 
favorable biophysical properties of disulfide-
rich cyclic peptides. To date, the most 
commonly used method for the head-to-tail 
cyclization of peptides has been native chemical 
ligation. In recent years, however, enzyme-
mediated cyclization has become a promising 
new technology due to its efficiency, safety and 
cost-effectiveness. Sortase A (SrtA) is a 
bacterial enzyme with transpeptidase activity. 
It recognizes a C-terminal penta-amino acid 
motif ‘LPXTG’ and cleaves the amide bond 
between Thr and Gly to form a thioacyl-linked 
intermediate. This intermediate undergoes 
nucleophilic attack by an N-terminal poly-Gly 
sequence to form an amide bond between the 
Thr and N-terminal Gly. Here, we demonstrate 
that sortase A can successfully be used to 
cyclize a variety of small disulfide-rich peptides, 
including the cyclotide kalata B1, α-conotoxin 
Vc1.1 and  sunflower trypsin inhibitor 1 (SFTI-
1). These peptides range in size from 14 to 29 
amino acids and respectively contain three, two 
or one disulfide bond within their head-to-tail 
cyclic backbones. Our findings provide proof-
of-concept for the potential broad applicability 
of enzymatic cyclization of disulfide-rich 
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peptides with therapeutic potential. 
 
INTRODUCTION     
     Disulfide-rich cyclic peptides are generating 
great interest in the field of drug design because of 
their remarkable stability towards enzymatic, 
thermal or chemical attack (1). Additionally, 
anecdotal evidence of some of them being orally 
bioavailable in indigenous medicine applications 
(2) has recently received support from studies 
demonstrating oral activity of engineered cyclic 
peptides in animal pain models (3,4). Several 
classes of cyclic peptides, including the sunflower 
trypsin inhibitors and cyclotides have now been 
discovered in a variety of plant species (5). In 
addition to the plant-derived cyclic peptides, 
disulfide-rich peptides isolated from cone snails, 
including α-conotoxins, have successfully been 
cyclized (3,6) and are showing promise as 
potential treatments for neuropathic pain (3). 
      Sunflower trypsin inhibitor 1 (SFTI-1) 
comprises 14 amino acids with a head-to-tail 
cyclized backbone. It was isolated from sunflower 
seeds and can specifically inhibit trypsin activity 
at 0.1 nM (7), which makes it the smallest and 
most potent serine proteinase inhibitor known. It 
was also reported to have inhibition activity 
against the epithelial serine protease matriptase at 
subnanomolar concentration (8). Its structure 
consists of two antiparallel β-strands connected by 
an extended loop and a sharp hairpin turn caused 
by a cis-proline residue. The β-strands are 
constrained by a single disulfide bond, which 
stabilizes the molecule and divides it into two 
regions – the active site loop and cyclization loop 
(7) (Fig. 1A). 
    Cyclotides are characterized by the combination 
of head-to-tail backbone cyclization and six 
conserved Cys residues forming a distinctive 
disulfide linkage pattern in which one disulfide 
bond passes through a ring formed by two other 
disulfide bonds (9,10) (Fig. 1B). The combination 
of a cyclic backbone and a knotted arrangement of 
three disulfide bonds is known as the cyclic 
cystine knot (CCK) motif and this motif is 
believed to be responsible for their exceptional 
stability towards chemical, enzymatic, or thermal 
degradation (1). Although thought to have a 
natural function as defense molecules in plants via 
their pesticidal activities (11-13), cyclotides 
possess a range of pharmaceutically interesting 
biological activities, including uterotonic (2), anti-
HIV (14), antimicrobial (15), insecticidal (11,16) 
activities, and are cytotoxic to tumour cells (17,18). 
Thousands of cyclotides are thought to exist in 
nature and more than 250 sequences have been 
described so far (http://www.cybase.org.au) (19), 
making them one of the most abundant plant 
protein families discovered. 
    Cyclotides are able to accommodate the 
synthetic introduction of a range of biologically 
active sequence motifs in the backbone loops 
between the conserved Cys residues while 
retaining thermal, chemical and enzymatic 
stability. This tolerance to sequence substitutions 
makes them ideal scaffolds for the development of 
stable peptide-based drugs incorporating epitopes 
of therapeutic value. For example, a kB1 hybrid, 
with an anti-angiogenic epitope incorporated into 
loop 3, combined anti-angiogenic activity with the 
native stability of kB1 (20). Likewise, molecules 
possessing activity against foot-and-mouth disease 
(21), inhibitory activity against β-tryptase and 
human leukocyte elastase (22), angiogenic activity 
(23), and the ability to antagonize intracellular p53 
degradation (24) have also been achieved by 
grafting relevant bioactive epitopes into the 
cyclotides MCoTI-I or MCoTI-II. The capacity to 
target intracellular sites is consistent with a range 
of recent biophysical studies demonstrating the 
ability of disulfide-rich cyclic peptides to 
internalize into cells (24-28).    
       As well as being valuable scaffolds, naturally 
occurring cyclic peptides such as cyclotides and 
SFTI-1 have inspired the concept of using 
artificial head-to-tail backbone cyclization as a 
stabilizing strategy for peptides and proteins of 
therapeutic interest (3,6). For example, Clark et al. 
showed that cyclization of α-conotoxin Vc1.1, a 
potential neuropathic pain treatment, engendered it 
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with orally activity (3). Thus, great interest has 
been shown in the development of cost-effective 
and efficient methods for the N- to C-terminal 
backbone cyclization of synthesized or expressed 
proteins (29,30). In the case of cyclic Vc1.1 
(cVc1.1) the termini of the naturally occurring 16 
residue peptide were covalently linked using a 6 
amino acid linker as illustrated in Fig. 1C (3). 
    Currently, the most widely-used strategy for 
backbone cyclization of synthetic peptides is 
native chemical ligation (NCL) (31,32), which 
utilizes an N-terminal cysteine and a 
functionalized C-terminus to form a thioester-
linked intermediate that undergoes an S, N acyl 
migration to form a native peptide bond (32). In 
general peptides are synthesized using solid phase 
peptide synthesis (SPPS), using either t-
butoxycarbonyl (Boc) or 
fluorenylmethyloxycarbonyl (Fmoc) protection. 
Despite the usefulness of NCL for splicing or 
cyclizing protein, there is still a demand for 
alternative methods of amide bond formation that 
are chemoselective, rapid, cheap, safe and waste-
free (30). Moreover, the requirement for an N-
terminal cysteine and a C-terminal thioester in 
NCL is not always compatible with Fmoc SPPS or 
recombinant expression. Accordingly, a number of 
different approaches to backbone cyclization have 
been developed (29), including expressed protein 
ligation (EPL) (33,34), intein-mediated protein 
trans-splicing (35) and genetic code 
reprogramming (36). 
    Recently, a family of thiol-containing 
transpeptidases, known as the sortases, were found 
to successfully cyclize linear proteins (37-40). 
Sortases are found in most Gram-positive bacteria 
where their primary function is to attach surface 
proteins to the bacterial cell wall (41). This 
ligation reaction has been exploited for a variety of 
protein engineering purposes, in most cases 
utilizing sortase A (SrtA) from Staphylococcus 
aureus (42). SrtA recognizes a 5-residue sequence 
motif, LPXTG (X = any residue), and cleaves the 
peptide bond between the Thr and Gly residues 
forming an acyl enzyme intermediate between a 
cysteine at the active site of SrtA and the 
carboxylate at the truncated C terminus of the 
substrate (43,44). Although in a natural system 
this covalent intermediate is resolved by 
nucleophilic attack from a pentaglycine side chain 
in a peptidoglycan precursor, a variety of glycine-
based nucleophiles can activate SrtA-catalyzed 
transpeptidation (38). The result is the efficient 
attachment of various moieties to the protein 
substrates and it has been applied to site-specific 
protein labelling (45), PEGylation (46), protein 
thioester generation (47) and protein-protein 
fusion (48). When such glycine-based 
nucleophiles originate from the N-terminus of the 
substrate, intramolecular transpeptidation reactions 
occur to yield covalently closed (circular) 
polypeptides by amide bond formation between 
the two termini (38-40). So far this approach has 
been examined only for a limited number of 
possible substrates and has not been explored for 
disulfide-rich peptides. 
    In the current study we demonstrate the efficient 
enzymatic cyclization of disulfide-rich peptides, 
including SFTI-1, cVc1.1 and kalata B1 (kB1), 
containing one, two or three disulfide bonds, 
respectively, by SrtA without the need for a 
thioester linker and using Fmoc chemistry. This 
study provides a proof-of-concept that SrtA 
mediated ligation can be utilized to cyclize 
disulfide-rich peptides ranging from the simple 
one-disulfide containing SFTI-1 to the complex 
cyclic cystine knot containing cyclotide structure 
of kB1 while retaining the native disulfide bond 
connectivity that is vital for the stability of these 
proteins. Fig. 1D summarizes the cyclization 
strategy for kB1.  
 
EXPERIMENTAL PROCEDURES 
Peptide synthesis- The linear peptides- 
[GGG]kB1[TGG], [G]Vc1.1[GLPETGGS], and 
[GG]SFTI-1[LPETGG] were synthesized by solid-
phase peptide synthesis using an automatic peptide 
synthesizer (Symphony®, Protein technologies, 
Inc.) following standard 9-
fluorenylmethoxycarbonyl (Fmoc) chemistry on a 
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2-chlorotrityl chloride resin. Acetamidomethyl 
(Acm) protecting groups were used on Cys4 and 
Cys17 of [G]Vc1.1[GLPETGGS] for selective  
disulfide bond (CysII-CysIV) formation. Cleavage 
of the peptide from the resin was achieved using 
trifluoroacetic acid (TFA):triisopropylsilane 
(TIPS):water=95:2.5:2.5 at room temperature (RT) 
for 2 h. The TFA was evaporated, and the peptide 
was precipitated with ice-cold diethyl-ether, and 
dissolved in 50% acetonitrile (ACN) containing 
0.05% TFA and lyophilized. Wild type Vc1.1 and 
SFTI-1 were prepared as described previously 
(3,49). 
    SrtA expression- The plasmid of and  
recombinant expression protocol for 
Staphylococcus aureus SrtA, which comprises the 
catalytic domain (residues 60 to 206 with a N-
terminal hexahistidine tag) was obtained from and 
as described by Popp et al. (50). Briefly, an 
overnight culture of Escherichia coli BL21 (DE3) 
transformed with SrtA plasmid was cultured in the 
presence of kanamycin (50 μg/mL) until OD600 
reaches ~0.7. The protein expression was induced 
by adding isopropyl β-D-thiogalactopyranoside 
(IPTG) to a final concentration of 1 mM for 3 h at 
37°C. The cells were then harvested by 
centrifugation at 7000 g at 4°C for 10 min. Cells 
were then resuspended in ice-cold lysis buffer (50 
mM Tris-HCl, pH 8.0, 150 mM NaCl, 25 mM 
imidazole, and 10% glycerol) and lysed by passing 
through a cell disrupter (TS Series Bench Top, 
www.constantsystems.com) operating at 26 kpsi. 
The cell debris was removed by centrifugation at 
12,000 g at 4°C for 30 min. The lysate was 
subjected for immobilised metal ion affinity 
chromatography using a 5 mL Ni-NTA FF column 
(GE healthcare, Uppsala, Sweden). The column 
was washed extensively with lysis buffer after 
sample loading and SrtA was eluted with a linear 
gradient over 10 column volume using elution 
buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 
500 mM immidazole). Fractions containing SrtA 
were buffer exchanged (50 mM Tris-HCl, 150 mM 
NaCl, and 10% glycerol) concentrated by using a 
centrifugal concentrator (<10 kDa). The SrtA was 
then stored at -80ºC until further use. The protein 
concentration was calculated by its extinction 
coefficient at 280 nm.  
(http://web.expasy.org/protparam/).   
     Oxidative folding- The linear 
precursor[GGG]kB1[TGG] was oxidized in 50% 
isopropyl alcohol (v/v)/0.1 M NH4HCO3 with 1 
mM reduced glutathione at pH 8 for 20 h at room 
temperature (51). The progress of oxidation was 
monitored by analytical reversed-phase high 
performance liquid chromatography (RP-HPLC) 
with a gradient from 0 to 50% ACN (0.05% TFA) 
in 50 min at a flow rate of 0.3 mL/min using an 
analytical C18 column (Agilent ZORBAX 300SB-
C18, 5 µm 2.1x150 mm). The oxidation yield was 
calculated based on HPLC profile. The mixture 
was then purified by RP-HPLC using a 0.5% 
gradient and the molecular weight was confirmed 
by mass spectrometry. Native kB1 was isolated 
from Oldenlandia affinis as described previously 
(9,52). 
    Both linear precursor [G]Vc1.1[GLPETGGS] 
and cyclic reduced [G]Vc1.1[GLPET] were 
oxidized in 0.1 M NH4HCO3 at 0.1 mg/mL 
concentration for 24 h to form disulfide bond CysI-
CysIII. Purified Vc1.1 (both linear and cyclic) with 
one disulfide bond was then dissolved in 50% 
acetic acid to a final concentration of 0.5 mg/mL 
under N2. Excess iodine dissolved (10 equivalents 
with respect to the Acm-protected Cys) in 50% 
acetic acid was added until the colour of reaction 
became yellow and the reaction was left at RT for 
24 h. The reaction was quenched by addition of 
ascorbic acid until the solution became colourless 
followed by RP-HPLC purification using a 
gradient of 0-60% acetonitrile in 60 min. 
    Cyclization- The concentration of modified kB1 
was determined by its molar extinction coefficient 
at 280 nm using NanoDrop2000c (Thermo 
Scientific). Linear oxidized [GGG]kB1[TGG] and 
linear precursor [GG]SFTI-1[LPETGG] (150 μM) 
were incubated with SrtA (50 μM) in the reaction 
buffer (50 mM Tris, pH 7.5, 150mM NaCl, 10mM 
CaCl2) at 37°C until the reaction was completed. 
The cyclization progress was monitored using RP-
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HPLC with a gradient from 0 to 50% ACN (0.05% 
TFA) in 50 min at a flow rate of 1 mL/min using 
an analytical C18 column (GraceSmartTM RP18, 5 
µm 4.6X150 mm). After completion of cyclization 
the reaction was loaded to semi-preparative C18 
column (Phenomenex, Jupiter 5UC18, 300 Å, 
250x10.0 nm, 5 µm), eluted with a gradient from 
36 To 45% ACN (0.05% TFA) in 30 min at a flow 
rate of 3 mL/min. The molecular mass of purified 
cyclo-[GGG]kB1[T] was confirmed by Matrix-
assisted laser desorption/ionization time of flight 
(MALDI-TOF). The fractions showing the correct 
mass were lyophilized for further assays. The 
concentration of Vc1.1 was also determined as 
described above. 10 µM linear precursor 
[G]Vc1.1[GLPETGGS] was incubated with 0.2 
µM SrtA in the reaction buffer containing 10 mM 
TCEP for 24 h at 4°C. SrtA was then removed 
from the sample using a 5 mL Ni-NTA FF column 
(GE healthcare, Uppsala, Sweden) and the flow-
through containing cyclic reduced 
[G]Vc1.1[GLPET] was collected and purified by 
RP-HPLC for oxidation.  
  As there are no aromatic residue available, the 
concentration of SFTI-1 was determined at 214 
nm using the NanoDrop2000c (Thermo Scientific) 
UV-Vis function with the extinction coefficient 
calculated based on the equation of ɛ214nm=(nAA-
1+nN+nQ)2846+nF7200+nH6309+nW22735+nY575
5 (53). 150 µM [GG]SFTI-1[LPETGG] and 50 
µM SrtA was incubated in the reaction buffer at 
37⁰C with pH adjusted to 8.5 to form disulfide 
bond at the same time. The progress of cyclization 
was monitored using analytical RP-HPLC with a 
gradient from 0 to 50% ACN (0.05% TFA) in 50 
min at a flow rate of 1 mL/min using an analytical 
C18 column (GraceSmartTM RP18, 5 µm 4.6x150 
mm). 
    Nuclear magnetic resonance analysis- cyclo-
[GGG]kB1[T] was dissolved in 90% H2O/10% 
D2O (v/v) or 100 % D2O to a final concentration 
of 1 mM and pH 6.1 (54). Cyclo-
[G]Vc1.1[GLPET] and cyclo-[GG]SFTI-1[LPET] 
were dissolved in 90% H2O/10% D2O (v/v) to a 
final concentration of ~1 mM and pH 3.1. All two-
dimensional (2D) nuclear magnetic resonance 
(NMR) spectra were acquired at 298 K. Spectra 
recorded for assignments and Hα secondary 
chemical shifts analysis included TOCSY with a 
80 ms mixing time and NOESY with a 200 ms 
mixing time. All spectra were acquired on a 
Bruker Avance 600 MHz NMR spectrometer 
equipped with a cryogenically cooled probe 
(Bruker, Karlsruhe, Germany). Water suppression 
for 2D TOCSY and 2D NOESY were achieved by 
using excitation sculpting (55). Spectra were 
recorded with 2048 data points in the direct F2 
dimension and 600 increments in the indirect F1 
dimension. Additional spectra recorded for cyclo-
[GGG]kB1[T] to be used in full structure 
calculations were NOESY with 100 ms mixing 
time as well as E.COSY (56), DQF-COSY as well 
as 13C-HSQC to produce the carbon chemical 
shifts. All spectra were processed using Topspin 
(Bruker) and analysed by CCPNMR (57) and 
Xeasy (58). The temperature coefficients were 
determined from recording TOCSY spectra from 
283 to 303 K in steps of 10 K. Chemical shifts 
were referenced to internal 2, 2-dimethyl-2-
silapentane-5-sulfonate (DSS) at 0.0 ppm (59). 
The peaks in the NOESY spectra with mixing 
times of 100 ms and 200 ms were manually picked 
and intra-residual and sequential NOEs were 
assigned followed by a full list of inter-proton 
distance being generated from chemical shifts and 
NOE intensities using the AUTO function in 
CYANA (tolerances used for CYANA were set to 
0.02 ppm for both indirect and direct 1H dimension) 
(60). Several rounds of AUTO including 
additional restraints such as disulfide bonds, 
hydrogen bonds and dihedral-angle restrains 
derived from TALOS+ were run to ensure correct 
peak assignment. Hα, HN, Cα, Cβ chemical shifts 
derived from 1H-1H NOESY and 1H-13C-HSQC 
were used to generate ϕ and ψ backbone dihedral 
angles using TALOS+ (61). The ANNEAL 
function in CYANA was used to perform 10000 
steps torsion angle dynamics to generate an 
ensemble from which 20 with the lowest penalty 
function were chosen for further analysis. Several 
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rounds of ANNEAL were run to resolve distance 
and dihedral constraints violations. Using 
protocols from the RECOORD database (62), 50 
structures were calculated using CNS (63) with 
force fields distributed with Haddock 2.0 (64) and 
refined in a water shell (65) as previously 
described (66). A set of 20 structures with no NOE 
violations of greater than 0.3 Å and dihedral 
violations greater than 3.0 degrees was chosen for 
MolProbity analysis (67). MOLMOL (68) was 
used for generating figures and final 
superimposition.  
     Hemolytic activity assay on [GGG]kB1[T]- 
The hemolytic assay was conducted as described 
previously (69). Briefly, erythrocytes were 
isolated from human blood and washed in 
phosphate-buffered saline (PBS, pH 7.4) with 
repeated centrifugation at 1,500 x g. The 
hemolytic activities of cyclo-[GGG]kB1[T], linear 
oxidized [GGG]kB1[TGG] and kB1 were 
determined with eight concentration points of from 
300 µM to 1.17 µM by serial dilution with a 2-fold 
interval with a final volume of 20 μL per well in a 
96-well plate. Triton X-100 solution (1%, v/v, 20 
μL) was used as a positive control to achieve the 
100% lysis, and PBS solution (20 μL) a negative 
control. 100 μL of erythrocyte stock solution was 
added to each well and incubated at 37°C for 1 h. 
After centrifugation of intact cells from the 96-
well plate, the supernatant of each well was 
measured by visual absorption spectroscopy at 415 
nm. Each experiment was performed in triplicate. 
    Serum stability assay on [GGG]kB1[T]- The 
stability of cyclo-[GGG]kB1[T] in human serum 
was evaluated using a method described 
previously (23). Briefly, human serum from male 
AB plasma (Sigma-Aldrich) was centrifuged at 
17,000g for 10 minutes to remove the lipid 
component. The resultant supernatant was 
collected and incubated for 15 minutes at 37°C 
before the assay. Cyclo-[GGG]kB1[T], linear 
oxidized [GGG]kB1[TGG]  and kB1 were tested 
at a final concentration of 20 μM. Stock solutions 
of peptides were diluted 1:10 with human serum 
whereas the dilution with PBS was negative 
controls and a linear 12-mer peptide tested in 
parallel was served as a positive control of the 
peptidase activity of the serum. Controls and test 
peptides were incubated at 37°C and 40 μL of 
samples were taken for measurements at time 
points of 0, 1, 2, 3, 5, 8, 11, and 24 h. Serum 
proteins in samples were denatured with 40 μL 6 
M urea at 4°C for 10 minutes and precipitated with 
additional 40 μL 20% trichloroacetic acid at 4°C 
for 10 minutes. The supernatant containing 
peptides was recovered by centrifugation at 17,000 
g for 10 minutes. 100 μL of supernatant from each 
time point of the serum-treated and PBS-treated 
(control) peptides was injected and analysed in 
triplicate on an analytical RP-HPLC column 
(Phenomenex) at a flow rate of 0.3 mL/min with a 
gradient of 0 to 50% ACN over 50 minutes. The 
retention time for each peptide was determined by 
PBS control at the 0 time point. The stability of 
each peptide at each time point was calculated as 
the percentage of the integrated peak area of the 
serum-treated peptide over that of the 0-hour 
serum-treated peptide on RP-HPLC at 215 nm.  
 
RESULTS 
    Protein production and purification- Linear 
precursors, with a SrtA recognition motif (LPXTG) 
at the C-terminus and a oligoglycine motif at the 
N-terminus (full sequence [GGG]kB1[TGG]:  
GGGCGETCVGGTCNTPGCTCSWPVCTRN
GLPVTGG, [G]Vc1.1[GLPETGGS]: 
GGCCSDPRCNYDHPEICGLPETGGS, and 
[GG]SFTI-1[LPETGG]: 
GGGRCTKSIPPICFPDLPETGG, with the 
native sequence in bold), were assembled using 
automated Fmoc chemistry, cleaved from the resin 
with TFA and purified using RP-HPLC. No 
oxidation of cysteine residues was observed during 
the purification process, as determined using mass 
spectrometry. The molecular mass and purity were 
confirmed using mass spectrometry and analytical 
RP-HPLC, respectively.  
    Oxidation and cyclization of [GGG]kB1[TGG]- 
The oxidative folding of the linear precursor 
[GGG]kB1[TGG] was monitored by RP-HPLC 
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(Fig. 2A) and the yield of correctly folded product 
was ~27% based on RP-HPLC peak integration. 
Following oxidative folding, linear 
[GGG]kB1[TGG] was purified by RP-HPLC and 
the correct folding was confirmed by NMR 
analysis (data not shown). For completeness, the 
stability of native kB1 in the SrtA reaction buffer 
was confirmed by the unchanged peak area in RP-
HPLC analysis after incubation of the native form 
for 24 h (data not shown).   
   In preliminary experiments two approaches were 
used to obtain oxidized, cyclic kB1 using SrtA 
mediated cyclization. First, linear reduced 
[GGG]kB1[TGG] was cyclized using the SrtA 
reaction buffer but with the addition of 2 mM of 
the reducing agent TCEP. The peptide was then 
oxidized after completion of the cyclization 
reaction. Second, the linear peptide 
[GGG]kB1[TGG] was oxidized prior to 
cyclization with SrtA, which proceeded without 
the addition of reducing agent to the reaction 
buffer. Cyclization prior to oxidation resulted in 
higher yields of cyclic reduced peptide as 
determined by RP-HPLC (~80%, data not shown), 
but subsequent oxidative refolding yielded several 
isomers (<10% yield for each isomer, data not 
shown), presumably due to misfolding during the 
oxidation reaction. Oxidation prior to cyclization 
resulted in a predominance of correctly folded 
peptide and this approach was therefore used for 
subsequent experiments. 
    Cyclization of 150 μM of linear oxidized 
[GGG]kB1[TGG] with 50 μM SrtA was 
monitored over 24 h using RP-HPLC (Fig. 2B). 
The reaction was not extended beyond 24 h due to 
the possibility of a competing hydrolysis reaction 
in which SrtA irreversibly hydrolyzes the LPVTG 
motif (70). After 24 h, ~49% of linear, oxidized 
[GGG]kB1[TGG] was converted to the cyclic 
product (highlighted in Fig. 2B). MALDI-TOF 
analysis of the highlighted peak fraction showed a 
monoisotopic mass (3162.92 Da) corresponding to 
that of cyclo-[GGG]kB1[T] (Fig. 2B), which was 
purified to >95% purity. Interestingly, the elution 
time of this peak (40.8 min) was similar to that of 
native kB1 (Fig. 2C) despite the additional amino 
acids in the sequence. Apart from this peak, two 
other peaks, at approximately 37 min and 40 min, 
appeared to be intermediate species in the 
cyclization reaction as their abundance over time 
was negatively correlated with the abundance of 
correctly folded cyclo-[GGG]kB1[T] (Fig. 2B). A 
small peak appearing  at approximately 42.8 min 
contained a peptide with the mass corresponding 
to that of cyclo-[GGG]kB1[T]. This peak also 
increased during the course of the experiment and 
is most probably an alternatively folded form of 
the peptide (Fig. 2B).  
Characterization of the cyclo-[GGG]kB1[T] by 
NMR- The NMR signals of cyclo-[GGG]kB1[T] 
were well-dispersed in the amide proton region, 
indicating the peptide is folded and has a well- 
defined structure. The individual amino acid spin 
systems were readily assigned using the sequential 
assignment procedure based on TOCSY and 
NOESY spectra (71). Cyclization was confirmed 
based on observation of a sequential αHi-HNi+1 
NOE between Thr30 and Gly31, indicative of the 
amide linkage of the C-terminal LPVT and N-
terminal GGG motif (Fig. 3). 
Chemical shifts are extremely sensitive to the 
local chemical environment, and Hα chemical 
shifts were thus used to compare the structure of 
cyclo-[GGG]kB1[T] to native kB1. Overall, the 
chemical shift differences between the two 
molecules are minimal (Fig. 3). With the 
exception of residues 1 and 27-33 (numbering 
system in Fig. 3), which are in loop 6 and either 
very close to or part of the SrtA sorting motif, no 
other cyclo-[GGG]kB1[T] residue exhibited 
significant deviations from the corresponding 
residue in native kB1. The very small shifts from 
random coil values for residues 1 and 27-33 of 
cyclo-[GGG]kB1[T] indicate that this region is 
disordered and this was confirmed in the 3D 
structure of cyclo-[GGG]kB1[T] (Fig. 4A). The 
solution structure was calculated using CYANA 
(60) followed by refinement in a water shell using 
CNS (63) based on 388 NOE distance restraints, 
53 dihedral angle restraints, including 26 ϕ, 20 ψ 
 Sortase A as a tool for cyclizing disulfide-rich peptides 
This is a post-print version of the following article: Jia, Xinying, Kwon, Soohyun, Wang, Ching-I Anderson, Huang, 
Yen-Hua, Chan, Lai Y., Tan, Chia Chia, Rosengren, K. Johan, Mulvenna, Jason P., Schroeder, Christina I. and Craik, 
David J. (2014) Semienzymatic cyclization of disulfide-rich peptides using sortase A. Journal of Biological 
Chemistry, Papers in Press : 1-25. 
 
and 6 χ1 dihedral angle restraints and 5 hydrogen 
bonds derived from temperature coefficient data 
(Table 1). The 20 conformers with the lowest 
energy superimposed with a backbone root mean 
square deviation (RMSD) of 0.53 ± 0.14 Å across 
resides 1-24 (Fig. 4A). Comparison of the cyclo-
[GGG]kB1[T] structure with that of native kB1 
(PDB ID: 1NB1) shows them to be very similar 
except for the more flexible loop 6 of cyclo-
[GGG]kB1[T] is (Fig. 4B). 
    Hemolytic activity and serum stability assay on 
cyclo-[GGG]kB1[T]- Native kB1 possesses mild 
hemolytic activity (15,51), which is undesired in a 
pharmaceutical context. Thus, to assess the effects 
of SrtA cyclization on the novel kB1 analogue, the 
hemolytic activity of cyclo-[GGG]kB1[T] and 
linear oxidized [GGG]kB1[TGG] was determined 
and compared with the native peptide. Compared 
to native kB1 both peptides exhibited significantly 
less hemolytic activity (Fig. 5A). After 24 h 
incubation, 50 μM of native kB1 lysed 64% of 
human erythrocytes whereas in the same time 
period only 6% or 2% of erythrocytes were lysed 
by the same concentration of cyclo-[GGG]kB1[T] 
or linear oxidized [GGG]kB1[TGG], respectively. 
The reduced hemolytic activity is consistent with 
previous mutagenesis studies on kB1, which 
showed that linearization or strategic replacement 
of certain residues can abrogate hemolytic activity 
(72,73). 
    To determine the effects of SrtA-mediated 
cyclization on the stability of the peptide, cyclo-
[GGG]kB1[T] was incubated in human serum. 
Encouragingly, its stability was comparable to that 
of native kB1, with only a slight reduction in 
peptide survival observed. After a 24 h incubation, 
77.4% and 95.9% of the starting concentration of 
cyclo-[GGG]kB1[T] and kB1 respectively was 
still present (Fig. 5B). Interestingly, 71% of linear 
oxidized [GGG]kB1[TGG] also remained in 
human serum after 24 h. In contrast, a linear 12-
mer control peptide, without any disulfide bond, 
was completely degraded within the first hour. 
    Oxidation and cyclization of 
[G]Vc1.1[GLPETGGS]- α-conotoxin Vc1.1 was 
successfully synthesized with a SrtA sorting motif 
at the C-terminus and an additional Gly residue at 
the N-terminus. Acm protecting groups on Cys4 
and Cys17 were used for selective disulfide bond 
formation of CysII-CysIV (Fig. 6A). As for cyclo-
[GGG]kB1[T], two approaches, namely oxidation 
prior to cyclization or cyclization prior to 
oxidation, were attempted to obtain the cyclo-
[G]Vc1.1[GLPET]. The former approach gave rise 
to only a low yield (~1%) of oxidized product 
following Acm removal. In contrast, isomerization 
during oxidative folding was averted by cyclizing 
the linear precursor [G]Vc1.1[GLPETGGS] prior 
to oxidation. The cyclization performed in the 
presence of 10 mM TCEP resulted in one major 
product with ~50% yield. The two disulfide bonds 
in the cyclic reduced [G]Vc1.1[GLPET] were then 
successfully formed via a two-step oxidation 
process with ~15% yield. The linear precursor 
[G]Vc1.1[GLPETGGS], cyclic reduced 
[G]Vc1.1[GLPET] and cyclic oxidized 
[G]Vc1.1[GLPET] (hereafter named cyclo-
[G]Vc1.1[GLPET]) showed a change in retention 
time after each reaction (Fig. 6B). The molecular 
mass and purity of the desired products for each 
step were confirmed by MALDI-TOF and RP-
HPLC (Fig. 6B).  
   NMR analysis of cyclo-[G]Vc1.1[GLPET]- The 
structure of cyclo-[G]Vc1.1[GLPET] was deduced 
using secondary Hα chemical shifts determined 
from TOCSY and NOESY spectra. A comparison 
of the secondary shifts of cyclo-[G]Vc1.1[GLPET] 
with both native and chemically cyclized Vc1.1 (3) 
suggested no significant difference in the overall 
structure. Cyclization of cyclo-[G]Vc1.1[GLPET] 
was confirmed by observation of  a sequential Hα-
NHi+1 NOE between the C- and N-termini. 
   SrtA reaction for SFTI-1- For this single 
disulfide-bonded peptide the SrtA reaction was 
performed at pH 8.5 to achieve cyclization and 
oxidation in a one-pot reaction. After 9 h, ~70% of 
the linear precursor had been converted to the 
cyclic oxidized form based on the RP-HPLC 
profile (peak at 20 min, Fig. 6C). The mass of 
cyclic oxidized [GG]SFTI-1[LPET] was 
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confirmed by MALDI-TOF (Fig. 6C). After 24 h 
incubation the peak at 20 min decreased and a 
peak at 22.8 min increased in height and was 
found to contain both cyclic oxidized and 
hydrolysed linear [GG]SFTI-1[LPET].   
    NMR analysis of cyclo-[GG]SFTI-1[LPET]- 
Purified cyclized and oxidized cyclo-[GG]SFTI-
1[LPET] and wild type SFTI-1 (both peptides >95% 
pure) were analysed using TOCSY and NOESY 
experiments. Two distinct conformations, in an 
approximate 9:1 ratio, were observed for cyclo-
[GG]SFTI-1[LPET]. The secondary shifts of the 
major conformation were almost identical with 
those of wild type SFTI-1 (Fig. 6D). The minor 
conformation appears to be due to cis-trans 
isomerisation of a proline residue. Pro8 in wild 
type STFI-1 is in the cis-conformation, with a 
strong NOEs observed between Ile7 Hα to Pro8 
Hαi+1. By contrast, in cyclo-[GG]SFTI-1[LPET] 
two sets of NOEs interacting with either δ-proton 
or α-proton of Pro8 were observed, suggesting that 
Pro8 exists in both cis and trans conformations 
(49).  
 
DISCUSSION 
    Disulfide-rich cyclic peptides offer an attractive 
framework for the development of stable bioactive 
peptides with pharmaceutical potential. They 
display a remarkable degree of functional 
plasticity and high stability. Accordingly, interest 
has been shown both in the cyclization of linear 
disulfide-rich peptides (especially those isolated 
from venoms), as well as the development of 
native cyclotides as therapeutics and in their use as 
scaffolds for the grafting of pharmaceutically 
relevant epitopes onto the native cyclotide 
framework (74,75). A bottleneck in the 
development of these peptides as potential 
therapeutics, though, is the production of linear 
precursors and their subsequent cyclization and 
folding. NCL (using Boc-chemistry) has been the 
preferred strategy for the production of disulfide-
rich cyclic peptides, but this approach requires 
reaction conditions that cannot always be achieved 
using Fmoc chemistry or recombinantly expressed 
proteins. We therefore investigated SrtA-mediated 
cyclization as a mechanism for the increased 
efficiency of one of the steps in cyclic peptide 
production, namely head-to-tail cyclization of 
synthetically produced peptides. Specifically, we 
explored the possibility of using SrtA to 
enzymatically cyclize SFTI-1, Vc1.1 (with a linker) 
and kB1, and showed that SrtA offers an efficient, 
safe and cost-effective method for the cyclization 
of disulfide-rich peptides ranging in size from 14 
to 29 amino acids with 1-3 disulfide bonds.  
    The presence of a native Leu-Pro-Val in loop 6 
of kB1 made this peptide an ideal model for 
cyclization using SrtA. These three residues 
fortuitously form a part of the penta-amino acid 
sorting motif, LPXTG, and cyclization was 
achieved with minimal disruption to the native 
sequence of kB1. In NCL-based synthesis of kB1, 
the cyclization and oxidation is carried out in a 
one-pot fashion. However, the reaction requires a 
two-step procedure when using SrtA for 
cyclization, with oxidation occurring either after 
or before SrtA mediated cyclization. In our hands, 
the order of the reaction, i.e. oxidation/cyclization 
vs cyclization/oxidation, had a significant effect on 
the yield of correctly folded peptide. Despite the 
minimal changes introduced in kB1 by SrtA 
cyclization no correctly folded peptide was 
produced when oxidation occurred after 
cyclization. Small changes in the amino acid 
composition of cyclotides can have profound 
effects on the refolding of synthetic forms (6,20) 
and it is possible that the introduction of the 
TGGG amino acid sequence in loop 6 of kB1 had 
a negative effect on the oxidative refolding of the 
cyclic form. The proximity of the cyclization point 
to CysI (Fig. 1) might also have adversely affected 
oxidative folding. The only region of significant 
structural perturbation in cyclo-[GGG]kB1[T] was 
for the Leu-Pro-Val residues immediately 
preceding CysI and, when combined with restraints 
imposed by cyclization, conformational variations 
in this region of the reduced, cyclized peptide 
might have prevented correct disulfide formation.   
Production of correctly folded cyclo-
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[GGG]kB1[T] was achieved by oxidative 
refolding prior to cyclization with SrtA. 
Monitoring of the cyclization reaction showed 
what appeared to be intermediates at various 
stages of the reaction, (Fig. 2B)  but by 24 h the 
reaction had efficiently converted the linear 
peptides to the cyclic form in ~49% yield.  
   Several pieces of NMR evidence support that 
cyclo-[GGG]kB1[T] adopts the fold of native kB1: 
(i) Pro20 adopts a cis-conformation as in native 
kB1; (ii) The HN of Trp19 is not observed in 
TOCSY spectra but is observed in NOESY spectra, 
as characteristically applies to kB1; (iii) The HB 
of Pro20 is shifted upfield to -0.26 ppm; (iv) The 
protonation/deprotonation of Glu3 significantly 
affects the chemical shifts of HN of Asn11 and 
Thr12; (v) The χ1 dihedral angles of all six 
cysteines residues agree with those for kB1, 
providing strong evidence for an identical 
disulfide connectivity. Consistent with this 
connectivity, NOEs between Cys1 Hβ2/Hβ3 to 
Cys15 Hβ3 and Cys10 Hβ2/Hβ3 to Cys22 Hβ2 
were observed (NOEs between Cys5 Hβ and 
Cys17 Hβ could not be unambiguously identified 
due to extensive spectral overlap). Interestingly, 
NOEs between Hβ protons of non-connected 
cysteine residues, including Cys10-Cys15, Cys1-
Cys22 and Cys15-Cys22 were also observed, but 
this is in complete accordance with a study on 
native kB1 by Rosengren et al (54) where it was 
suggested that for cyclic cystine knot peptides, Hβ 
cross-peaks are not the preferred diagnostic tool 
for determining disulfide connectivity due to the 
close proximity of all disulfide bonds. From the 
extensive evidence noted above, especially the fact 
that the two peptides share identical χ1 dihedral 
angles for all the Cys residues, we were confident 
that we produced cyclo-[GGG]kB1[T] with the 
native disulfide connectivity. Thus, we calculated 
the structure of cyclo-GGGkB1T using the 
cysteine connectivities as native kB1 (PDB ID: 
1NB1). 
    The hemolytic activity of cyclo-[GGG]kB1[T] 
was significantly reduced compared to native kB1. 
As structural perturbation of cyclo-[GGG]kB1[T] 
was minimal (Fig. 5) the loss of hemolytic activity 
is presumably due to the effects of the residues 
introduced into loop 6 upon cyclization. Previous 
grafting experiments utilising kB1 have also 
shown the abrogation of hemolytic activity after 
relatively minor changes to the primary sequence; 
for example the grafting of the vascular 
endothelial growth factor sequence (RRKRRR) 
into loops 2, 3, 5, or 6 significantly reduced the 
hemolytic activity of kB1 (20). The effects of 
single point mutations on the hemolytic activity of 
kB1 have also been extensively studied (73). The 
hemolytic activity of kB1 was dramatically 
reduced by Ala substitution on a specific set of 
residues, including the last three residues of loop 6 
(Leu27, Pro28 and Val29). Similar results were 
observed during Lys substitution at the same 
positions (69). Barry et al (72) also noted 
complete loss of hemolytic activity of linearized 
kB1 with RNGLP sequence deletion. All the 
studies suggest that the hemolytic activity of kB1 
can be diminished when a less hydrophobic 
residue is introduced into the last three positions of 
loop 6. In kalata B2, a close homolog of kB1, loop 
6 forms part of a hydrophobic interface that 
mediates interactions between the cyclotide and 
the plasma membrane (76). In this context, the loss 
of hemolytic activity after the introduction of 
additional residues to loop 6 suggests the 
interruption of critical membrane/peptide 
interactions in this region of the peptide.  
    The residues introduced into loop 6 might have 
also contributed to the slight reduction in stability 
of cyclo-[GGG]kB1[T] relative to the native 
peptide. Chemical shifts for these residues differed 
little from random coil values, suggesting that 
structural disorder at the cyclization point made 
the peptide slightly more susceptible to plasma 
proteases than native kB1. This disorder was also 
confirmed in the NMR solution structure of 
[GGG]kB1[T], with loop 6 displaying markedly 
increased disorder compared to native kB1. The 
serum stability results show that the cystine knot 
formation is crucial for stability as linear oxidized 
[GGG]kB1[TGG] was largely (~71%) intact after 
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24 h.  
    The sortase-catalyzed process requires modest 
modifications in order to render peptides amenable 
to cyclization. In this work the cyclization point 
was chosen on the basis of a pre-existing Leu-Pro-
Val motif in loop 6 which overlapped with the 
SrtA recognition motif. This fortuitous 
coincidence resulted in the introduction of three 
fewer non-native amino acids than would be 
required using a different cyclization point. 
Analysis of chemical shifts showed that apart from 
differences of ~0.5 ppm in the Leu-Pro-Val 
residues of the cyclization point, the remainder of 
the SrtA cyclized peptide exhibited very little 
structural perturbation. Loop 6 of cyclotides 
exhibits the greatest diversity in structure, 
sequence and length (77) and the lack of structural 
perturbation in this case reflects the ability of this 
loop to accommodate a range of structural motifs 
without affecting the overall fold of the peptide. 
Accordingly, the use of this loop for cyclization 
should provide a convenient and simple 
mechanism for production of synthetic cyclotides 
for a variety of applications.  
    To test the generality of SrtA-mediated 
cyclization we investigated if it could be applied to 
other small disulfide-rich peptides such as α-
conotoxin Vc1.1 and SFTI-1. MALDI-TOF and 
NMR analysis confirmed that their cyclized and 
oxidized structures were similar to the native 
structures. In contrast to kB1, 9 h of SrtA reaction 
appeared to be sufficient to obtain the maximum 
yield for cyclo-[GG]SFTI-1[LPET], presumably 
due to its smaller size. Beyond this incubation 
time, some hydrolysis of the peptide was found to 
occur, resulting in linearization since the final 
product still contains a LPETG motif. Interestingly, 
introduction of the sortase-motif in SFTI-1 (cyclo-
[GG]SFTI-1[LPET]), gave rise to cis-trans 
isomerization of Pro8, as highlighted by the 
observation of strong NOEs between both Ile7Hαi 
– Pro8Hαi+1 (cis) and Ile7Hαi – Pro8Hδi+1 (trans). 
Although the LPXTG motif was introduced to the 
cyclic loop of SFTI-1, presumably placing the 
motif next to the Asp14 made structure of the 
peptide less constrained than the wild type. This is 
consistent with a previous study showing that Ile7, 
Pro8, Pro9 and Asp14 are important for structural 
integrity (49). In that study, when Asp14 was 
replaced with Ala the turn region was destabilized, 
resulting in cis-trans isomerization of Pro13 (49). 
Even though the isomerization site is different, 
introduction of the SrtA sorting motif appears to 
have destabilized the turn region, giving rise to the 
minor conformation observed by NMR.    
    The work described here demonstrates the 
applicability of the SrtA method for the 
cyclization of different classes of disulfide-rich 
peptides without significant structural perturbation 
to the overall peptide fold. We have shown that 
this method is applicable whether the peptides are 
cyclic in their native form such as SFTI-1 
containing one disulfide-bond, or kB1 with a three 
disulfide-bond cyclic cystine knot motif or 
whether the peptide is linear in its native form and 
the cyclization site is introduced by the addition of 
a linker, such as for cVc1.1. SrtA-mediated head-
to-tail cyclization, works optimally with peptides 
larger than 12-mers, excluding the SrtA sorting 
signal (40). Cyclotides are typically 28-37 amino 
acids in size, making all characterized cyclotides 
suitable for SrtA cyclization. In addition, other 
disulfide-rich peptides, for example conotoxins 
(78) or defensins (79,80), are also within this size 
range, making SrtA mediated cyclization a 
possibility for a wide range of peptides of 
therapeutic interest. Importantly, the ability to 
place the SrtA tags at any position within a peptide 
sequence makes it possible to introduce 
cyclization points anywhere in the peptide of 
interest and thus minimise disruption of 
biologically or structurally important motifs. Thus 
peptide bond closure of linear precursors through 
sortase-catalysed circularization represents a 
simple, safe and effective method, not only for the 
production of synthetic cyclotides, but also for the 
introduction of increased stability and 
bioavailability to other disulfide-rich peptides with 
therapeutic value. 
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FIGURE LEGENDS 
 
FIGURE 1. (A) Representation of the sequence and structure (PDB ID: 1JBL) of native SFTI-1, (B) 
native kalata B1 (PDB ID: 1NB1) (kB1) which is the prototypic cyclotide, (C) native linear Vc1.1 (PDB 
ID: 2H8S) which has been cyclized by a 6-amino acid linker using native chemical ligation (3,32). The 
disulfide bonding network is shown as sticks, with the cysteine residues numbered. Amino acids are 
represented by their one-letter code. (D) The linear oxidized [GGG]kB1[TGG] contains a SrtA 
recognition sequence (LPVTG) and undergoes an intramolecular transpeptidation reaction catalyzed by 
SrtA to form cyclic oxidized [GGG]kB1[T] (cyclo-[GGG]kB1[T]).  
FIGURE 2. (A) RP-HPLC profile of [GGG]kB1[TGG] oxidation at 0 and 20 h. A major peak of linear 
precursor peptide and linear oxidized product is marked with schematic representation of the peptide. (B) 
Time course analysis of the SrtA reaction progress monitored by RP-HPLC. Aliquots were taken from the 
reaction mixture at 0, 4, 8, 12 and 24 h, and loaded onto an analytical RP-HPLC. (C) MALDI-TOF 
analysis of linear precursor, linear oxidized [GGG]kB1[TGG], native kB1 peptide and cyclic oxidized 
[GGG]kB1[T] (clockwise). Cyclo-[GGG]kB1[T] revealed a mass corresponding to the linear oxidized 
[GGG]kB1[TGG] minus two glycines and a water molecule, indicative of the formation of a amide bond 
between the N-and the C-terminal. (D) Analytical RP-HPLC profile of purified cyclo-[GGG]kB1[T] 
(above) and co-injection of cyclo-[GGG]kB1[T] and native kB1 (below) to demonstrate their only 
slightly different retention times. 
FIGURE 3. Hα secondary shift comparison of native kB1 (empty squares with dashed line) and cyclo-
[GGG]kB1[T] (filled squares with solid line). The Hα secondary shifts were calculated by subtracting 
random coil shifts (81) from the experimental Hα shifts. The box highlights loop 6, where the extra 
residues TGGG were introduced by the SrtA-mediated cyclization. 
FIGURE 4. (A) Superimposition of the 20 lowest energy structures of cyclo-[GGG]kB1[T] shown in 
blue with disulfide bonds shown in orange. (B) Comparison of cyclo-[GGG]kB1[T] in blue with native 
kB1 in red (PDB ID:1NB1) by superimposition of residues 1-24 of cyclo-[GGG]kB1[T] against residues 
1-24 of the native kB1 structure. Disulfide bonds shown in orange highlighting the similarities between 
the two structures across loop 1-5 and the increased flexibility of loop 6 by insertion of the SrtA sorting-
motif. RMSD across heavy backbone atoms for residues 1-24 cyclo-[GGG]kB1[T] / 1-24 kB1 is 0.461.  
FIGURE 5. Hemolytic and serum-stability assay on cyclo-[GGG]kB1[T]. (A) Percentage of hemolysis 
by cyclo-[GGG]kB1[T] compared to native kB1 included as a positive control. (B) Percentage of peptide 
remaining after 0, 1, 2, 3, 5, 8, 11 and 24 h incubation in human serum. The data are presented as means ± 
standard deviation (SD). 
Figure 6. (A) Cyclization strategy for [G]Vc1.1[GLPETGGS] and [GG]SFTI-1[LPETGG] by SrtA. (B) 
Retention time and MALDI-TOF analysis of linear precursor [G]Vc1.1[GLPETGGS], cyclic reduced and  
cyclic oxidized [G]Vc1.1[LPET]. The peptide status is shown with schematic representations. (C) One-
pot reaction of oxidation and cyclization of [GG]SFTI-1[LPETGG]. Time course analysis of SrtA 
reaction by RP-HPLC (left), MALDI-TOF data (right) of linear precursor [GG]SFTI-1[LPETGG] and 
cyclic oxidized(cyclo)-[GG]SFTI-1[LPET]. (D) Hα secondary shift comparison of cyclo-[GG]SFTI-
1[LPET] and wild type SFTI-1. (E) Hα secondary shift comparison of cyclo-[G]Vc1.1[GLPET], wild 
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type Vc1.1, and the orally active analgesic peptide cVc1.1 (3). The sorting motif is shown in a dashed box. 
 
 
Table 1: Energies and structural statistics for the family of 20 lowest energy cyclo-[GGG]kB1[T] 
structuresa.  
Energies (kcal/mol) 
Overall -975.7 ± 38.5 
Bonds 20.5 ± 1.4 
Angles 52.5 ± 4.3 
Improper 17.4 ± 2.3 
Van der Waals -96.1 ± 4.7 
NOE 0.3 ± 0.03 
cDih 0.3 ± 0.2 
Dihedral 129.7 ± 1.6 
Electrostatic -1100.3 ± 36.4 
MolProbity Statistics  
Clashes (>0.4 Å / 1000 atoms) 12.8 ± 4.1 
Poor rotamers 0.3 ± 0.4 
Ramachandran Outliers (%) 0.0 ± 0.0 
Ramachandran Favoured (%)b 87.6 ± 2.7 
MolProbity score 2.3 ± 0.2 
MolProbity score percentile 56.2 ± 13.4c 
Atomic RMSDd (Å)  
Mean global backbone (1-24) 0.53 ± 0.14 
Mean global heavy (1-24) 1.11 ± 0.25 
Mean global backbone (1-33) 1.53 ± 0.58 
Mean global heavy (1-33) 1.90 ± 0.53 
Distance Restraints  
Intraresidue (i-j = 0) 59 
Sequential (/i-j/ = 1) 169 
Medium range (/i-j/ < 5) 53 
Long range (/i-j/ > 5) 107 
Hydrogen bonds 10 
Total 398 
Dihedral angle restraints  
φ 26 
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Ψ 20 
χ1 6 
Total 53 
Violations from experimental restraints  
Total NOE violations exceeding 0.3 Å 0  
Total Dihedral violations exceeding 3.0° 0  
a Based on structures with highest overall MolProbity score (82). 
b The remaining 12.4% are found in the allowed regions of the Ramachandran plot. 
c 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. 
d RMSD calculated using MOLMOL (68).  
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 NMR spectra of cyclo-[GG]SFTI-1[LPET]. TOCSY spectrum (upper panel) and NOESY spectrum 
(lower panel) recorded at 298K, 90% H2O/10% D2O. 
 NMR spectra of cyclo-[G]Vc1.1[GLPET]. TOCSY spectrum (upper panel) and NOESY spectrum (lower 
panel) recorded at 298K, 90% H2O/10% D2O. There was a subset of extra residues found to be from Gly1 
to Ser4 and Glu14 to Gly22 with overlapping or similar chemical shifts to the major conformer. This is 
caused by cis-trans isomerization of Pro19 in the linker (GLPETG), but it did not affect the overall 
structure of cyclo-[G]Vc1.1[GLPET].   
 TOCSY (the upper panel) and NOESY (the lower panel, the enlarged HA region) spectrum of cyclo-
[GGG]kB1[T] recorded at 298 K, 90% H2O/10% D2O. The upper panel shows the spin systems by 
vertical lines, except Trp19 which was not observable in the TOCSY, while the lower panel highlights the 
sequential walk, except for Pro13, Pro20 and Pro28. 
